Upper Gastrointestinal (lips to ileocecal valve, including esophagus and stomach)

E439: Cost-effectiveness of adjuvant imatinib in intermediate-risk gastrointestinal stromal tumors (GIST)

E440: Tumor Infiltrating Lymphocytes are Significantly Increased with Neoadjuvant Chemotherapy Treatment in Patients with Resectable Gastric Cancer

E441: Lymph node status in patients with CDH1 mutation who undergo prophylactic total gastrectomy.

E442: Risk assessment for robotic to open gastrectomy conversion in gastric cancer patients

E443: Impact of Immigration and Race-Ethnicity on Gastric Cancer Incidence: An analysis of Multi-Ethnic Cohort study

E444: Heat-Shock Proteins in esophagogastric cancer. A meta-analysis

E445: Neoadjuvant Chemotherapy for Early-Stage Gastric Cancer: Is There a Potential Survival Benefit?

E446: Lower Prevalence of Actionable Biomarker Targets in Gastric Cancer Peritoneal Carcinomatosis

E447: Gastric cancer disparities among Asians, Asian Americans, and White Americans: Insights from two leading cancer centers in East and West

E448: Reasons for surgical attrition among non-metastatic upper gastrointestinal cancer patients; a single institutional experience

E449: Post-Gastrectomy Weight Loss in the Modern Era

E450: The Influence of Lymph Node Ratio on Survival in Gastric Adenocarcinoma Patients Following Radical Gastrectomy

E451: Impact of Neoadjuvant Chemotherapy on Sarcopenia in Gastric Adenocarcinoma

E452: Classification of Gastric Neuroendocrine Tumors and Associations with Survival

E453: Disparities in Multiagent Perioperative Chemotherapy for Gastric Cancer

E454: Patient Perceived Impact of Quality-of-Life Following Gastrectomy for Gastric Cancer

E455: Impact of Gastric Cancer Tumor Downstaging Following Neoadjuvant Therapy on Overall Survival: A National Cancer Database Analysis

E456: Immune cells in gastrointestinal stromal tumors vary with treatment

E457: National Trends in Minimally Invasive Surgery for Clinical T3-4 Esophageal Cancer. A New Standard of Care for Locally Advanced Disease?

E458: The Impact of Therapeutic Treatment Delay on Survival Outcomes in Gastric Cancer

E459: Pancreas Preserving Distal Duodenectomy Compared to Pancreaticoduodenectomy for Primary Duodenal Adenocarcinoma: Experience at a Quaternary Referral Center.

E460: Long-Term Quality of Life and Survivorship Priorities in Esophagogastric Cancer Patients

E461: Validation of a Disease-Specific Survival Model for Resected Entero-Pancreatic Neuroendocrine Neoplasms

E462: Impact and Disparities of Neoadjuvant Chemoradiation on Overall and Three-Year Conditional Survival in Locally Advanced Esophageal Cancer

E463: Characterizing Conditional 90-Day Mortality and Associated Risk Factors After Discharge from Complex Esophageal and Gastric Cancer Surgery

E464: Clinicopathological Factors associated with Pathological Complete Response in Patients Undergoing Neoadjuvant Therapy Followed by Esophagectomy

E465: Evolving Landscapes in Gastric Cancer Treatment Over a Decade

E466: The Role of Metastasectomy in Patients with Liver-Only Metastases from Gastroesophageal Cancer

E467: Contemporary Trends, Management, and Outcomes for Patients with Diffuse Type Gastric Cancer

E468: Small bowel cancers: a population-based analysis of epidemiology, treatment and outcomes in Ontario, Canada from 2005-2020

E469: Body composition and postoperative outcomes after minimally invasive esophagectomy

E470: VirMAP for Cancer: Characterization of the intratumoral virome in virally-associated cancers and a resource for investigators

E471: Streamlining care for gastric cancer patients utilizing intra-operative ultrasound

E472: Defining the relationship between hospital surgical volume and hospital delivery of multimodal treatment for gastroesophageal adenocarcinoma: a retrospective cohort study.

E473: Comparison of pathological complete response and survival outcomes in squamous cell carcinoma of oesophagus patients post CROSS protocol and curative surgery – a propensity matched analysis of real world data.

E474: Comparison of post-operative outcomes in the bariatric versus gastric cancer population

E475: Establishing the Facility Volume to Outcome Relationship for Minimally Invasive Gastrectomy for Gastric Cancer: a National Review of Outcomes

E476: Impact of Delays in Surgery after Preoperative Chemotherapy for Gastric Cancer

E477: Lymphadenectomy for Gastric Cancer in the FLOT Era: Analysis of the National Cancer Database

E478: Exploring the Impacts of the Covid 19 pandemic on Gastric and Esophageal Cancer Severity

E479: Clinicopathologic outcomes in individuals with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)

E480: Outcomes of Three-Port Minimally Invasive Transthoracic Esophagectomy for Resectable Esophageal Cancer in Prone Position

E481: Trends in Textbook Outcome after Esophageal Cancer Resection in the United States, 2016-2021

P66: CTLA-4 Blockade Increases Tumor-infiltrating CD8+ Cells in a Syngeneic Model of Gastric Cancer

P67: Long-Term Outcomes in Patients with Gastric Cancer after Conversion from Positive to Negative Peritoneal Cytology

P68: Systemic Treg depletion inhibits tumor growth in gastrointestinal stromal tumor (GIST)

P69: The Effect of Laparoscopic Gastric Ischemic Preconditioning Prior to Esophagectomy on Anastomotic Stricture Rate: A Prospective Cohort Study

P70: Does Minimally Invasive Gastrectomy Impact Return to Intended Oncologic Therapy for Gastric Cancer?

P71: Surgical Decision Making in Locally Advanced Esophageal Adenocarcinoma

P72: Tumour Microenvironment Score but not the Cancer Genome Atlas or Asian Cancer Research Group classification is an independent prognostic factor for disease-free survival in non-metastatic gastric cancer

P73: Adjuvant Chemotherapy for Node-Negative Gastric Adenocarcinoma after Neoadjuvant Chemotherapy and Gastrectomy